Oxford BioDynamics announces completion of the results of the EpiSwitch Breast Cancer test on a cohort of 236 samples spanning different grade of cancer, tumour size, lymph node involvement, hormone receptor and HER2 status. The test demonstrates high accuracy and is performed under high standards of ISO 13485:2003, ISO 9001:2008 and FDA 21 CFR Part 820 requirements.